InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partners to a "market perform" rating.
InflaRx (NASDAQ:IFRX) was given a new $2.00 price target on by analysts at Leerink Partners.
InflaRx (NASDAQ:IFRX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference